Micro Cap Insider
CeCors Inc (OTCMKTS: CEOS) Opportunity Mushrooms with Disabled Veterans
CeCors Inc (OTCMKTS: CEOS) is at heart a mushroom company with products on the shelf that is transforming into a disabled veteran benefits company. Many have heard of magic mushrooms, psychedelic mushrooms, and psilocybin and their medicinal benefits. One of the biggest consumers of these products is disabled veterans. The core company is PsyKey which is a vertically integrated mushroom company developing medicinal products for healthcare professionals and consumers. The products come primarily from functional mushrooms that have specific purposes. Their mushrooms are cleverly mixed with coffee pods as a delivery system that allows people to start their day off right.
While the company does have modest revenues from the sales of their core products, the sizzle is in the acquisition of VetComm Corp. announced in mid December. The reality was that this binding letter of intent was not taken seriously by market participants until they were beaten over the head with a video with the charismatic CEO of VetComm, Kate Monroe.
This video outlined her goal of onboarding 1.0 million veterans of the 14 million veterans eligible for disability to get their rating. If she accomplishes this goal she claims
“This would put $30 billion per month into the US economy”
The huge problem they are trying to solve is the simplification of the governmental claims process. These 14 million veterans eligible for benefits simply don’t have the energy to cut through the red tape and get a successful disability rating with the government. VetCOMM has a seasoned team that essentially handles the rating process for the vets. All the vets have to do is pay the monthly fee and answer the questions from VetComm.
1.0 Million Veteran Challenge
Anyone thinking that 1.0 million isn’t attainable is underestimating both the CEO Kate Monroe, a veteran herself from the Marine Corps, and the networking power of veterans. Veterans are a tight knit community. Think about it some of these vets were sitting in a foxhole and their life depended on their buddy doing his job. So when these vets sign up for VetComm and get a positive result and then call their buddy up and say trust me you need to do this, there is no waffling around. Vets will listen to other vets. This video from Randy Couture just shows you a hint of the star power they have behind this company.
The government set aside tens of billions of dollars for disabled veterans but navigating the rating process with the government paper pushers is worse than combat for some of these vets. They get discouraged and give up, that is where the tenacity of the VetComm team comes into play and knows how to successfully navigate the bureaucratic maze and get results for these veterans. VetComm just takes a flat fee for their service ($247 or $997) and the vets could receive thousands of dollars monthly depending on their level of injury. There is no reason not to try, and the company has a money back guarantee. Even more exciting is the back pay some of these vets could receive. Wait until some of the testimonials go viral. The website currently has real testimonials from veterans sharing their story of how easy it was to get rated. The message from VetComm is that there is nothing to lose and almost everyone walks away with something.
The CEO is a networking guru and has pictures with top politicians and generals all supporting her efforts. These are top politicians like Senator Ted Cruz, Roger Marshall, Earnest Grassley, John Cornyn, and Deb Fischer. Then there are the celebrity endorsements from Randy Couture, Ken Shamrock, Donald Trump, Jr., Sarah Palin, Matt Thomas of Parmalee, Carl Higbee, and Gretchen Carlson.
Revenue Estimates
The revenue off of her 1.0 million veteran goal could be $500 million considering that the average fee is about $500 dollars assuming the majority will opt for the do it yourself rating instead of the “Done-For-You” service. The company has no formal projections but if they do release something it could be a big catalyst. The costs of goods sold on this are marketing and the customer support line. VetComm is essentially getting a small sliver of the $30 billion monthly pot of money the government has agreed to pay out but hasn’t had to because the veterans haven’t filled out their paperwork. Kate Monroe is creating a social movement in the veteran community to take what they are owed and not let politicians repurpose those funds for other special interests
Acquisition Synergy
There is a sense of community that VetComm is trying to establish. Many of the vets that suffer from PTSD would be helped by the functional mushroom products. There is also a planned expansion of the product line that the company alluded to last year. A natural expansion of the line could mean that other products like gummy bears, capsules, or other delivery systems are introduced.
Financial Analysis
The company has 332 million shares in the O/S and has 148 million in the float. The current market cap is sitting at close to $10 million. Since they are an operational company with revenues they had their Shell Status designation removed from OTC Markets. The company has also openly stated that they are not going to reverse split the stock or take on additional dilution. This might be interpreted to mean that they won’t exceed the authorized limit of 500 million shares.
This means the VetComm acquisition is likely to be paid with treasury stock. In early 2022 87.75 million shares were brought back into treasury and could easily be reissued for the purchase. This is complete speculation because the details of the acquisition have yet to be released but the bread crumbs lead to a very shareholder friendly transaction.
Risks
There is a definitive deal to acquire VetComm, but investors are not privy to the terms of the deal. Therein lies the major risk. Investors have no idea how much dilution is possible in the acquisition nor do they know how strong the underlying business is. Dilution would have to be less than the authorized max. It’s impossible to tell if it’s a good deal or a bad deal, although their comments on social media demonstrate it’s going to be very positive. Leadership is a question too because there is no CEO at the helm. The filings show Amar Bhatal is the president and the CEO spot is vacant. While it’s reasonable to speculate that Kate Monroe would be the ideal candidate for CEO, she has no public market experience. If the VetComm acquisition were to fall apart many investors could be holding the bag because the underlying mushroom business has not generated sufficient earnings to support the public listing short term.
Investor Summary
The volume is just starting to ramp off of what looks like a long term bottom so there doesn’t appear to be much downside at the current stock price and plenty of upside to $.12. The mushroom industry is massive, but a unique opportunity exists in servicing veterans. VetComm is led by a charismatic CEO who might very well take over CEOS. Her social media standing suggests that she is going to use digital marketing and the power of veteran networking and endorsements to mobilize the veterans. This deal can almost be considered a Software as a Service (SaaS) deal as it contains those components. The goal of attaining 1.0 million veterans by year end could translate into massive revenues in the tens of millions or hundreds of millions with little to no customer acquisition acquisition costs (CAC). It’s too early to tell, but CEOS is one of those long term fundamental plays that should be held in a speculative portfolio. Should they complete the acquisition and give revenue estimates investors could see long term 12 – 18 month upside up to $1.00 assuming a fully diluted 500 million O/S and $500 million in revenues trading at a multiple of 1X sales. The downside risk is nominal given their rapidly expanding mushroom line that could be cash flow positive on its own this year.
Disclosure: MicroCapDaily has not been compensated for this article. This post was written by a guest contributor and posted on our website for free. The owners of MicroCapDaily have no position in any of the securities mentioned.
LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.
GAMMABODY™ PLATFORM
LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.
To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.
In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.
My big % winning day trade today was $LVTX.
All I did was follow the system.
It has a small float.
Fresh meet never pumped before.
Big News out.
Giant volume.
Why I jumped in early and took profits on the spike in volume. pic.twitter.com/2knPeC5RHz— Trader Brian Jones (@MasterBJones) June 2, 2023
As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates.
The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.
$LVTX $66mil mcap, $133mil in cash at the end of December, cash runway into 2026, median price target $13 (443% upside)
— Jake Weber (@BioStockAnalyst) June 2, 2023
Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.
Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.
$LVTX has three gamma-delta t cell drug candidates in early-stage trials, including collaboration with $SGEN for solid tumors.
— Jake Weber (@BioStockAnalyst) June 2, 2023
In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.
We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Featured
Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions
Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development. The clinical-stage biopharmaceutical company has entered into a take-private transaction with MPM BioImpact, representing a significant milestone for Reunion Neuroscience. The transaction is valued at $13.1 million, a 43.1% premium to Reunion’s common shares’ 30-day volume-weighted average price.
Going private is a significant step for Reunion Neuroscience, as it means that a sizeable private-equity group or consortium of private-equity firms will purchase or acquire the stock of the publicly traded corporation.
To Discover the Inside Scoop on REUN, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Under the terms of the Arrangement Agreement, all holders of outstanding common shares of Reunion will be entitled to receive $1.12 in cash for each share held immediately before the effective time of the Arrangement. However, the agreement’s closing is subject to several conditions, which must be met before the transaction can be completed.
$REUN she wants more
— JC Capital Consultants (@CapitalJc) June 1, 2023
Hostile takeover?
While management and the board think it is a significant milestone achieved, others think differently – an investor rights law firm, Halper Sadeh LLC, is currently investigating it… The sale of Reunion Neuroscience to affiliates of MPM BioImpact for $1.12 per share in cash is currently being investigated by Halper Sadeh LLC.
$REUN halted pending news
— Ralph (@StuckInStock) June 1, 2023
The investigation concerns whether Reunion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Reunion shareholders; (2) determine whether MPM is underpaying for Reunion; and (3) disclose all material information necessary for Reunion shareholders to assess and value the merger consideration adequately. On behalf of Reunion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
$Reun Reunion Neuro we are buying this little Gem up. Could see this at $3 in coming months. Great acquisition $13 ,million just for starters . Watch this space 💎
— The New Yorker (@TheNewY10001) June 1, 2023
Reunion Neuroscience’s stock performance has been relatively volatile in recent years. The stock’s median target price, according to analysts’ forecasts, is $5.00, but there is a wide range of estimates, with a high of $20.00 and a low of $0.73. The current consensus among polled investment analysts is to buy $REUN stock. However, they’re a pre-revenue clinical-stage biopharmaceutical company, which means the last earnings reported a loss in the current quarter’s earnings per share – they’ve yet to generate any significant revenue. Until recently, shareholders experienced a significant decline in the stock’s value this year and were down ~54% prior to the acquisition. There are ~9M shares in the float, with ~28% and ~13% held by insiders and institutional investors, respectively.
Solid scalp for a quick win on $REUN. Low float but not really that much volume so it appears to be done and tanking accordingly. Time for this old dog to go into town.
— You Enjoy Myself (@AddenoidalHonk) June 1, 2023
Overall, investors should carefully consider the potential risks and rewards associated with investing in Reunion Neuroscience, considering the wide range of price estimates and the company’s current financial performance. Thorough research and the advice of a financial professional are recommended before making any investment decisions.
We will update you on REUN when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Gerd Altmann from Pixabay
Featured
Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells
Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601. They tested it on lymphoma cells in the lab, and the results showed that MT-601 can kill lymphoma cells resistant to another treatment called CD19 CAR T therapy, which is fascinating news considering many patients who receive CD19 CAR T therapy still experience a relapse within a year.
“We have recently developed a long-term in vitro model to monitor the interaction of T cells with cancerous cells. Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited the growth of lymphoma cells as well as the growth of CD19 CAR-resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics. Marker has posted further details about this preclinical study on the Investor Relations section of its website.
$MRKR Marker Therapeutics reveals positive pre-clinical results of its MT-601 MultiTAA-Specific T Cell Product Candidate in lymphoma cells.
More Info: https://t.co/K3T6HXHIN8 $XBI $IBB $XPH $PPH pic.twitter.com/fCz9Dv1dS8
— Ozmosi (@OzmosiHealth) May 31, 2023
Dr. Smith continued, “Specifically, we have developed an in vitro model which reproduces the CD19 antigen-negative tumor that causes relapse and observed the following:
To Discover the Inside Scoop on MRKR, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
In this in vitro model, 98% of lymphoma cells were eliminated after a CD19-targeting CAR T cell product was administered.
Most Traded Tickers in premarket: $WLGS $AI $MRKR $TRVN $TSLA $NVDA $ARDS $VTGN $PLTR $FFIE pic.twitter.com/ytT4T40kPS
— DayRanger – Investors Underground (@DayRanger) May 31, 2023
While the CAR T cells significantly controlled lymphoma cell growth, we observed that three weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells resistant to CD19 CAR T cell administration started to grow.
These CD19 CAR-resistant lymphoma cells were tested for CD19 expression. They were shown to be negative for the CD19 surface antigen, which explained why they were no longer controlled with a second administration of anti-C19 CAR T cells, thus recapitulating the antigen-negative relapse observations in CAR relapsed/refractory lymphoma patients.
However, when MT-601, with its broad antigen recognition (Survivin, NY-ESO-1, WT-1, PRAME, MAGE-A4, SSX2), was added to this anti-CD19 CAR T cell resistant cell population, complete growth inhibition was observed.
These data highlight that MT-601 can potentially eliminate CD19 CAR T cell refractory tumors, indicating that MT-601 might offer a viable therapeutic option for lymphoma patients that have relapsed from previous CAR T cell interventions.”
MT-601 targets multiple substances on cancer cells and may provide longer-lasting results than CD19 CAR T therapy. Marker Therapeutics has started a clinical trial to test MT-601 on lymphoma patients who have relapsed after CD19 CAR T therapy or cannot receive it. The early lab results showed that MT-601 could inhibit the growth of lymphoma cells, including those resistant to CD19 CAR T therapy. The initial results have shown remarkable promise, and the team is thrilled to advance the testing of MT-601 in further clinical trials to evaluate its effectiveness and safety.
About Marker Therapeutics, Inc.
Marker Therapeutics is a company currently in the advanced stages of clinical research for developing innovative treatments in immuno-oncology. Their primary focus is on creating next-generation immunotherapies that utilize T cells, a type of immune cell, to target and fight against hematological malignancies (cancers of the blood, such as leukemia and lymphoma) and solid tumors (cancers that form in tissues or organs). These therapies aim to harness the immune system’s power to specifically recognize and eliminate cancer cells, offering potential new treatment options for patients with these types of cancers.
$MRKR 1.91 ready! Spike to follow 2.35ish
— Donnie Stocks (@DonnieStocks) May 31, 2023
Capital structure
Marker Therapeutics has an outstanding total of 8.8M shares and presents a relatively small float of 6.64M shares available for public trading. Insiders hold approximately 12.82% of the shares, while institutional investors hold around 22.63%. Examining their trading history, the average volume typically hovers around 100,000 shares. In light of the positive news today, the trading activity trended much higher, with an impressive 27M shares traded at time of writing. This translates to a 270-fold increase compared to their average volume, also 4x their float.
$mrkr low float, can go hard. pic.twitter.com/6dGTE8Ufau
— Nick Sullivan Life & Medicare Agency (@SprouttSales) May 31, 2023
It is essential to recognize the high volatility and rapid movements associated with Marker Therapeutics’ stock, primarily driven by the limited availability of shares. Such stocks tend to attract the interest of day and swing traders, given their propensity for swift gains or losses based on trading strategies. As evidence, a single positive news catalyst in the biotech sector can trigger a substantial surge in stock price and exponentially increase trading volume to unprecedented levels.
We will update you on MRKR when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum
Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions
Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells
Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership
Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI
-
Uncategorized6 months agoMeta Materials Inc (OTCMKTS: MMTLP) Enormous Short Position in Trouble as Next Bridge Hydrocarbons Set to Stop Trading (George Palikaras & John Brda on Corporate Action)
-
Micro Cap Insider2 years agoMedium (KOK PLAY) The Parabolic Rise of Metal Arts (OTCMKTS: MTRT)
-
Media & Technology2 years agoHealthier Choices Management Corp. (OTCMKTS: HCMC) Powerful Comeback Brewing as PMI Patent Infringement Lawsuit Moves Forward
-
Media & Technology3 years ago
AMECA Mining RM; the Rise of Southcorp Capital, Inc. (OTCMKTS: STHC)
-
Media & Technology2 years agoSNPW (Sun Pacific Holding Corp) Power Brewing: 50MW solar farm project in Durango Mexico MOU with Atlas Medrecycler 48,000 SF New Partnership Queensland Australia Solar Farm.
-
BioPharma1 year agoAsia Broadband (OTCMKTS: AABB) On the Move Northbound Since Sub $0.08 Dip as Crypto Innovator Elevates AABB Crypto Exchange & Enters the NFT Space
-
Uncategorized7 months agoMeta Materials Inc (OTCMKTS: MMTLP) Short Squeeze S-1a4 Filing Signals S1 Approval Could Be Days Away (Next Bridge Hydrocarbons Spin-Off)
-
BioPharma2 years agoHumbl Inc (OTCMKTS: HMBL) Major Reversal as Powerful Advisor Rejoins the Team & Looks to Uplist to Major Exchange
